Clinical Trial Update: Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study update characterizes belinostat exposure across patients with different UGT1A1*28 genotypes (wild-type, heterozygous, homozygous).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Solid Tumors

Drugs mentioned

• BELEODAQ (BELINOSTAT)

Snippet

Sponsor: Acrotech Biopharma Inc. | Conditions: Solid Tumors, Hematological Malignancies | Phase 1 | Status: COMPLETED